MedTrace Logo

The AI Prognostic Assessment and Pathological Basis Research of Early HCC After Minimally Invasive Treatment

NCT04299919 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1200

Last updated 2020-03-09

No results posted yet for this study

Summary

The study evaluates artificial intelligence method based on multimodal magnetic resonance imaging (MRI) images and clinical data in preoperative prediction of prognosis in early hepatocellular carcinoma (HCC) patients treated with minimally invasive treatment. The correlation between prognosis-related MRI features and pathological features was studied through artificial intelligence method, so as to provide the interpretability of image features for predicting the prognosis of HCC patients treated with minimally invasive treatment.

Conditions

Interventions

PROCEDURE

Minimally invasive treatment

All hepatocellular carcinoma (HCC) patients received minimally invasive treatment, including transcatheter arterial chemoembolization (TACE), radiofrequency ablation (RFA) or combined.

PROCEDURE

Hepatectomy

All hepatocellular carcinoma (HCC) patients received hepatectomy.

Sponsors & Collaborators

  • The First Affiliated Hospital of Dalian Medical University

    lead OTHER

Principal Investigators

  • Ying Zhao, MD · The First Affiliated Hospital of Dalian Medical University

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-01
Primary Completion
2023-06-30
Completion
2024-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04299919 on ClinicalTrials.gov